Triple-Drug HCV Therapy for HIV-Coinfected Patients?

In studies presented at CROI 2012, triple-drug therapy led to more side effects and drug interactions than standard regimens — but also had a dramatically higher success rate.

The approval of the hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs) telaprevir and boceprevir in 2011 dramatically changed the treatment paradigm for patients infected with HCV genotype 1. However, the two drugs are currently licensed for use only in HCV-monoinfected patients and only in combination with peginterferon and ribavirin. At CROI 2012, researchers presented data on the risks and benefits of these drugs in HIV/HCV-coinfected patients.

In a company-sponsored, phase II trial of telaprevir, 60 HIV-infected patients with previously untreated HCV genotype 1 infection — 13 who were not taking antiretroviral therapy (ART) and 47 whose HIV infection was well controlled with either an efavirenz- or atazanavir-based regimen — were r…

Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Triple-Drug HCV Therapy for HIV-Coinfected Patients?

Topics

Author